Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one
2. 9 Hydroxy Risperidone
3. 9 Hydroxyrisperidone
4. 9 Oh Risperidone
5. 9-hydroxy-risperidone
6. 9-hydroxyrisperidone
7. 9-oh-risperidone
8. Invega
9. Invega Sustenna
10. Paliperidone
11. Palmitate, Paliperidone
12. R 76477
13. R-76477
14. R76477
15. Sustenna, Invega
1. 199739-10-1
2. Invega Sustenna
3. Xeplion
4. Invega Trinza
5. Ro92670
6. Ro 92670
7. Paliperidone Palmitate [usan]
8. R8p8usm8fr
9. 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-9-yl Palmitate
10. Jns010
11. Hexadecanoic Acid, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-4-oxo-4h-pyrido(1,2-a)pyrimidin-9-yl Ester
12. Chebi:83808
13. Jns-010
14. Ro-92670
15. R092670
16. (9rs)-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4h-pyrido(1,2-a)pyrimidin-9-yl Hexadecanoate
17. 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-9-yl Hexadecanoate
18. R-092670
19. Trinza
20. [3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl] Hexadecanoate
21. Hexadecanoic Acid, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl Ester
22. Unii-r8p8usm8fr
23. 9-hydroxyrisperidone Palmitate
24. Jns 010
25. Pp3m
26. Paliperidone Janssen
27. Palperidone Palmitate
28. Paliperidone Palmitate-[d4]
29. Schembl1871384
30. Chembl2107360
31. Schembl12415674
32. Hy-a0019a
33. Dtxsid70870217
34. Paliperidone Palmitate [mi]
35. Bcp08473
36. Paliperidone Palmitate [jan]
37. Mfcd24386477
38. S5624
39. Paliperidone Palmitate [vandf]
40. Paliperidone Palmitate [mart.]
41. Paliperidone Palmitate [who-dd]
42. Sb17398
43. Ncgc00522023-01
44. Paliperidone Palmitate [ema Epar]
45. Ac-32485
46. As-77089
47. Paliperidone Palmitate [orange Book]
48. Cs-0016387
49. Ft-0673476
50. D83646
51. Q27157250
52. 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-9-ylpalmitate
53. 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl Hexadecanoate
| Molecular Weight | 664.9 g/mol |
|---|---|
| Molecular Formula | C39H57FN4O4 |
| XLogP3 | 10.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 20 |
| Exact Mass | 664.43638447 g/mol |
| Monoisotopic Mass | 664.43638447 g/mol |
| Topological Polar Surface Area | 88.2 Ų |
| Heavy Atom Count | 48 |
| Formal Charge | 0 |
| Complexity | 1090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Xeplion is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.
In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine D2 Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)
Serotonin 5-HT2 Receptor Antagonists
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes. (See all compounds classified as Serotonin 5-HT2 Receptor Antagonists.)
N05AX13
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Avesta Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Solubilizers
Topical
Parenteral
Surfactant & Foaming Agents
Emulsifying Agents
Fillers, Diluents & Binders
Thickeners and Stabilizers
Lubricants & Glidants
Film Formers & Plasticizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
27
PharmaCompass offers a list of Paliperidone Palmitate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Paliperidone Palmitate manufacturer or Paliperidone Palmitate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Paliperidone Palmitate manufacturer or Paliperidone Palmitate supplier.
PharmaCompass also assists you with knowing the Paliperidone Palmitate API Price utilized in the formulation of products. Paliperidone Palmitate API Price is not always fixed or binding as the Paliperidone Palmitate Price is obtained through a variety of data sources. The Paliperidone Palmitate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A INVEGA TRINZA manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of INVEGA TRINZA, including repackagers and relabelers. The FDA regulates INVEGA TRINZA manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. INVEGA TRINZA API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of INVEGA TRINZA manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A INVEGA TRINZA supplier is an individual or a company that provides INVEGA TRINZA active pharmaceutical ingredient (API) or INVEGA TRINZA finished formulations upon request. The INVEGA TRINZA suppliers may include INVEGA TRINZA API manufacturers, exporters, distributors and traders.
click here to find a list of INVEGA TRINZA suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A INVEGA TRINZA DMF (Drug Master File) is a document detailing the whole manufacturing process of INVEGA TRINZA active pharmaceutical ingredient (API) in detail. Different forms of INVEGA TRINZA DMFs exist exist since differing nations have different regulations, such as INVEGA TRINZA USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A INVEGA TRINZA DMF submitted to regulatory agencies in the US is known as a USDMF. INVEGA TRINZA USDMF includes data on INVEGA TRINZA's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The INVEGA TRINZA USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of INVEGA TRINZA suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a INVEGA TRINZA Drug Master File in Korea (INVEGA TRINZA KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of INVEGA TRINZA. The MFDS reviews the INVEGA TRINZA KDMF as part of the drug registration process and uses the information provided in the INVEGA TRINZA KDMF to evaluate the safety and efficacy of the drug.
After submitting a INVEGA TRINZA KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their INVEGA TRINZA API can apply through the Korea Drug Master File (KDMF).
click here to find a list of INVEGA TRINZA suppliers with KDMF on PharmaCompass.
A INVEGA TRINZA written confirmation (INVEGA TRINZA WC) is an official document issued by a regulatory agency to a INVEGA TRINZA manufacturer, verifying that the manufacturing facility of a INVEGA TRINZA active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting INVEGA TRINZA APIs or INVEGA TRINZA finished pharmaceutical products to another nation, regulatory agencies frequently require a INVEGA TRINZA WC (written confirmation) as part of the regulatory process.
click here to find a list of INVEGA TRINZA suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing INVEGA TRINZA as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for INVEGA TRINZA API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture INVEGA TRINZA as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain INVEGA TRINZA and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a INVEGA TRINZA NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of INVEGA TRINZA suppliers with NDC on PharmaCompass.
INVEGA TRINZA Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of INVEGA TRINZA GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right INVEGA TRINZA GMP manufacturer or INVEGA TRINZA GMP API supplier for your needs.
A INVEGA TRINZA CoA (Certificate of Analysis) is a formal document that attests to INVEGA TRINZA's compliance with INVEGA TRINZA specifications and serves as a tool for batch-level quality control.
INVEGA TRINZA CoA mostly includes findings from lab analyses of a specific batch. For each INVEGA TRINZA CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
INVEGA TRINZA may be tested according to a variety of international standards, such as European Pharmacopoeia (INVEGA TRINZA EP), INVEGA TRINZA JP (Japanese Pharmacopeia) and the US Pharmacopoeia (INVEGA TRINZA USP).
